Inflammatory bowel disease: clinical aspects and established and evolving therapies
Top Cited Papers
- 1 May 2007
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 369 (9573), 1641-1657
- https://doi.org/10.1016/s0140-6736(07)60751-x
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- AbataceptNature Reviews Drug Discovery, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Systematic review: the effectiveness of budesonide therapy for Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitisDigestive Diseases and Sciences, 1995